1 active not recruiting, 1 recruiting, 1 unknown. 1 Early Phase 1, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Unknown 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Mediastinal B-Cell Diffuse Large Cell Lymphoma: new trials by email Literature Review of Mediastinal B-Cell Diffuse Large Cell Lymphoma trials Research Report on Mediastinal B-Cell Diffuse Large Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide - Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B | Phase 2 | Active not recruiting | Shanghai Ming Ju Biotechnology Co., Ltd. | 46 | 2023-11-03 | 2025-02-11 |
| Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers Hematolo-GIST Training, Participants Appointment - Lymphoma, B-Cell, Lymphoma | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 48 | 2023-07-03 | 2026-10-13 |
| An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma Anti CD30 CAR-T Cell Injection - Hodgkin Lymphoma, NK/T Cell Lymphoma | Early Phase 1 | Unknown | Zhejiang University | 9 | 2022-02-10 | 2022-01-26 |
Lymphoma, Large B-Cell, Diffuse (3) · Dendritic Cell Sarcoma, Interdigitating (1) · Hodgkin Disease (1) · Immunoblastic Lymphadenopathy (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma, Non-Hodgkin (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Lymphoma (2) · Lymphoma, B-Cell (2) · Histiocytic Disorders, Malignant (1) · Histiocytosis (1) · Lymphadenopathy (1)
Cyclophosphamide (1) · fludarabine (1) · relmacabtagene autoleucel (1)
Memorial Sloan Kettering Cancer Center (1) · Shanghai Ming Ju Biotechnology Co., Ltd. (1) · Zhejiang University (1)
China (2) · United States (1)
Depei Wu, PhD (1) · Huang He, PhD (1) · Kelly McConnell, PhD (1) · Weili Zhao, PhD (1)